Evidence map›Paper›PMID 40180620›Full record

ArticleDiscover oncology2025

Gut Escherichia coli promotes lung cancer by increasing circulating STAMBP production.

Xinpei Li, You Mo, Shijie Shang, Meng Wu, Shuling Ma, Zijun Zhai, Qian Song, Dawei Chen

Abstract read
In one paragraph

Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Targeting gut microbiota and metabolites in cancer radiotherapy.Clinical and translational medicine · 2025
    Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Xinpei LiShandong Provincial Key Laboratory of Precision Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, 250117, Shandong, China.
You MoShandong Provincial Key Laboratory of Precision Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, 250117, Shandong, China.
Shijie ShangShandong Provincial Key Laboratory of Precision Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, 250117, Shandong, China.
Meng WuShandong Provincial Key Laboratory of Precision Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, 250117, Shandong, China.
Shuling MaShandong Provincial Key Laboratory of Precision Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, 250117, Shandong, China.
Zijun ZhaiShandong Provincial Key Laboratory of Precision Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, 250117, Shandong, China.
Qian SongShandong Provincial Key Laboratory of Precision Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, 250117, Shandong, China. sqoxaid@163.com.
Dawei ChenShandong Provincial Key Laboratory of Precision Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, 250117, Shandong, China. dave0505@yeah.net.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundExcessive abundance of gut pathogens and inflammatory lung damage are potential risk factors for lung cancer. Nevertheless, the exact function of inflammatory proteins in mediating the nexus between gut microbiota and lung cancer remains elusive.

methodsWe first executed Mendelian randomization analysis with the inverse variance weighting method as the primary method, followed by a sensitivity analysis of the results. Finally, we carried out in vitro experiments and database analyses to corroborate our conclusions.

resultsAfter multiple tests, we identified that the gut genus Parasutterella and species Escherichia coli (E. coli) were tied a heightened risk of lung cancer, while Bacteroides salyersiae was a protective factor against lung cancer. Circulating STAM-binding protein (STAMBP) and C-C Motif Chemokine Ligand 23 were considered potential risk factors for lung cancer. In vitro experimental results indicated that the E. coli supernatant significantly induced lung cancer cell proliferation and cell cycle transition but suppressed cell apoptosis. Mechanistically, E. coli increases the production of STAMBP to promote lung cancer progression.

conclusionsOur results indicated that gut E. coli can potentially increase STAMBP secretion, thereby promoting lung cancer progression. This research delivers a new viewpoint for analyzing the carcinogenic mechanism of E. coli as well as the subsequent prevention and management of lung cancer.

Indexed as

Escherichia coliGut microbiotaInflammatory proteinsLung cancerSTAMBP

Identifiers

PMID40180620
PMCPMC11968627

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.